var data={"title":"Techniques and interpretation of HIV-1 RNA quantitation","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Techniques and interpretation of HIV-1 RNA quantitation</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/contributors\" class=\"contributor contributor_credentials\">Angela M Caliendo, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/contributors\" class=\"contributor contributor_credentials\">John G Bartlett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 08, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Human immunodeficiency virus type 1 (HIV-1) RNA can be measured using qualitative or quantitative techniques. Qualitative testing (commonly referred to as nucleic acid testing or NAT) is used as a screening test to identify HIV-infected individuals, such as screening possible blood donors. Quantification of HIV-RNA (viral load measurements) can be used as a diagnostic test in certain situations; however, the HIV viral load is primarily used for <span class=\"nowrap\">management/monitoring</span> of HIV-1-infected individuals.</p><p>This topic will address the laboratory methods for quantitation of HIV-1 RNA and the use of viral load for clinical management. Additional information on nucleic acid, HIV-2 RNA, and CD-4 cell count testing is found elsewhere. (See <a href=\"topic.htm?path=blood-donor-screening-laboratory-testing#H9\" class=\"medical medical_review\">&quot;Blood donor screening: Laboratory testing&quot;, section on 'HIV-1 and HIV-2'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hiv-2-infection#H15783706\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of HIV-2 infection&quot;, section on 'Testing for HIV-2 infection'</a> and <a href=\"topic.htm?path=techniques-and-interpretation-of-measurement-of-the-cd4-cell-count-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14118660\"><span class=\"h1\">THE USE OF HIV VIRAL LOAD MEASUREMENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies have found HIV-1 RNA levels to be a predictor of the time to progression to acquired immunodeficiency syndrome (AIDS) and death that is independent of CD4 cell counts [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/1-6\" class=\"abstract_t\">1-6</a>]. (See <a href=\"topic.htm?path=factors-affecting-hiv-progression#H2\" class=\"medical medical_review\">&quot;Factors affecting HIV progression&quot;, section on 'Laboratory markers of progression'</a>.)</p><p>Viral load measurements are also an important factor in selecting and antiretroviral therapy regimen and monitoring the response to treatment [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/7\" class=\"abstract_t\">7</a>]. The use of HIV-1 RNA measurements in clinical practice are discussed separately. (See <a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">&quot;Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient&quot;</a> and <a href=\"topic.htm?path=patient-monitoring-during-hiv-antiretroviral-therapy\" class=\"medical medical_review\">&quot;Patient monitoring during HIV antiretroviral therapy&quot;</a>.)</p><p>In specific situations (neonatal infection and acute infection), HIV-1 RNA levels also may be useful in establishing the diagnosis of HIV infection. However, in most other situations, combination tests that detect HIV p24 antigen and HIV antibodies are primarily used. (See <a href=\"topic.htm?path=screening-and-diagnostic-testing-for-hiv-infection\" class=\"medical medical_review\">&quot;Screening and diagnostic testing for HIV infection&quot;</a> and <a href=\"topic.htm?path=diagnostic-testing-for-hiv-infection-in-infants-and-children-younger-than-18-months\" class=\"medical medical_review\">&quot;Diagnostic testing for HIV infection in infants and children younger than 18 months&quot;</a> and <a href=\"topic.htm?path=acute-and-early-hiv-infection-clinical-manifestations-and-diagnosis#H986011160\" class=\"medical medical_review\">&quot;Acute and early HIV infection: Clinical manifestations and diagnosis&quot;, section on 'Diagnostic test performance in early HIV infection'</a>.) </p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">LABORATORY METHODS FOR QUANTITATION OF HIV-1 RNA</span></p><p class=\"headingAnchor\" id=\"H628267773\"><span class=\"h2\">Available tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are three real-time reverse transcriptase polymerase chain reaction (RT-PCR) commercial tests that are commonly used to quantify HIV-1 RNA from plasma samples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The COBAS <span class=\"nowrap\">AmpliPrep/COBAS</span> TaqMan HIV-1 Test version 2 (Roche Diagnostics) [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/8\" class=\"abstract_t\">8</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The RealTime HIV-1 (Abbott Molecular)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aptima HIV-1 Quant Dx Assay (Hologic; Marlborough, Massachusetts)</p><p/><p>Other viral load tests had been used in the past (Amplicor Monitor, bDNA, and NucliSens). However, these have been replaced by real-time RT-PCR assays, which are more sensitive (they detect 20 to 40 <span class=\"nowrap\">copies/mL</span> of HIV RNA), have a broad linear range (they detect virus to at least 10 million <span class=\"nowrap\">copies/mL),</span> and pose a lower risk of carry over contamination than prior PCR assays. (See <a href=\"#H4\" class=\"local\">'Quantification and linear range'</a> below.)</p><p>Studies of the three real-time RT-PCR tests have shown excellent agreement in viral load values between the COBAS TaqMan and Abbott RealTime tests [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/9\" class=\"abstract_t\">9</a>]. There is also very good agreement in viral load values between the Aptima test and the COBAS TaqMan and RealTime tests [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/10-12\" class=\"abstract_t\">10-12</a>]. However, the agreement is decreased at the lower limit of quantification of the tests [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/9,13\" class=\"abstract_t\">9,13</a>]. Thus, it is important to use the same assay when following HIV-1 RNA levels over time. If the viral load assay used to monitor a patient is changed, a new baseline viral load measurement should be obtained, especially when monitoring patients with low or undetectable viral loads. </p><p>An important difference between the real-time tests is the gene target; the COBAS TaqMan test targets both the <em>gag</em> gene and the long terminal repeat, the Aptima test targets the <em>pol</em> gene and long terminal repeat, while the Abbott RealTime test targets the integrase gene. With the increasing use of integrase inhibitors, monitoring for resistance mutations in the integrase gene is important to ensure that the primer and probe binding sites are not impacted, which could lead to under quantification of HIV-1 RNA. Active surveillance programs for this purpose have been implemented, and as of 2017, this has not been reported.</p><p>Some clinical laboratories test cerebral spinal fluid (CSF) specimens; however, this requires a separate validation process as HIV-1 RNA tests are not FDA approved for use on CSF. The use of CSF viral load testing is discussed elsewhere (see <a href=\"topic.htm?path=hiv-associated-neurocognitive-disorders-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis&quot;</a>). Viral load testing of other specimens (eg, dried blood spots, cervical fluid, semen) has only been used in the research setting. </p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Specimen collection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The real-time RT-PCR tests have been designed to measure HIV-1 RNA from plasma specimens. Finger prick samples have also been tested in the Abbott RealTime test, and due to reduced sample volume, the test had a lower limit of quantification of approximately 500 <span class=\"nowrap\">copies/mL</span> [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/14\" class=\"abstract_t\">14</a>].</p><p>For routine clinical use, the real-time PCR tests require between 0.5 and 1.0 mL of plasma. The blood should ideally be anticoagulated in EDTA (purple top tube) since the virus is most stable in this anticoagulant. Acid citrate dextrose (ACD) can also be used as an anticoagulant, but there may be a 15 percent decrease in the viral load measurement due to the volume of the anticoagulant [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/15,16\" class=\"abstract_t\">15,16</a>]. Blood anticoagulated in heparin is unacceptable for the RT-PCR assays. It is important to follow the recommendations for specimen collection outlined in the package insert since they may differ for each test.</p><p>Due to the instability of HIV-1 RNA in whole blood, it is critical to handle clinical specimens properly to minimize the risk of RNA degradation. Plasma should be separated within six hours of collection and ideally stored at -20&ordm;C, although plasma viral RNA is stable at 4&ordm;C for several days. Failure to separate plasma promptly may lead to degradation of viral RNA and a falsely decreased viral load measurement [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/15,16\" class=\"abstract_t\">15,16</a>]. In addition, viral load measurements may be reduced by as much as 50 percent if serum samples are used, probably due to trapping of the viral particles in the clot [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/16\" class=\"abstract_t\">16</a>]. For this reason, plasma specimens should be used when viral load measurements are followed over time.</p><p>Plasma preparation tubes (PPTs) contain a gel barrier that physically separates plasma from the cellular components, and have an advantage in that whole blood can be collected in these tubes and held at room temperature for up to six hours prior to centrifugation and shipped in their original tube at ambient temperature without affecting the viral load values [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/17\" class=\"abstract_t\">17</a>]. However, after centrifugation, PPTs should either be stored refrigerated or plasma should be removed from PPTs prior to freezing, as freezing the plasma samples in PPTs can falsely elevate the viral load values [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/18,19\" class=\"abstract_t\">18,19</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Quantification and linear range</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The available assays differ in their limit of quantification and linear range. The lower limit of quantification is a key characteristic of viral load assays, and how this parameter is defined is equally important. The limit of detection is best defined as the amount of nucleic acid that can be verified in 95 percent of replicate samples. Using this definition, the limit of quantification and linear range of the assays is as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The COBAS <span class=\"nowrap\">AmpliPrep/COBAS</span> TaqMan version 2 HIV-1 test &ndash; 20 to 10 million <span class=\"nowrap\">copies/mL</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The RealTime HIV-1 &ndash; 40 to 10 million <span class=\"nowrap\">copies/mL</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aptima HIV-1 Quant Dx test &ndash; 30 to 10 million <span class=\"nowrap\">copies/mL</span></p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">INTERPRETATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several issues that must be considered when interpreting the results of HIV-1 RNA measurements. These include the clinical significance of changes in viral load, the relationship of HIV-1 RNA to the CD4 cell count, and the possible presence of HIV-1 non-B subtypes.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Clinically significant changes in viral load</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>To determine if changes in viral load represent clinically significant changes in viral replication both intra-assay and biologic variation need to be considered. Each of the viral load assays has a low intra-assay variation, between 0.12 and 0.2 log<sub>10</sub>, on repeated testing of a single specimen [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/8,11,20-22\" class=\"abstract_t\">8,11,20-22</a>]. In general there is greater variability in the tests near the lower limit of detection. In clinically stable patients, HIV-1 RNA levels are relatively stable from week to week and month to month, provided antiretroviral therapy has not been initiated or changed. The biologic variability of viral RNA measurements is about 0.3 log<sub>10</sub> [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/23\" class=\"abstract_t\">23</a>]. </p><p>These data taken together have led to the recommendation that changes in HIV-1 RNA levels must exceed at least 0.5 log<sub>10</sub> or threefold in magnitude to represent biologically relevant changes in viral replication [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/23,24\" class=\"abstract_t\">23,24</a>]. It is important not to over interpret small increases or decreases in viral RNA.</p><p class=\"headingAnchor\" id=\"H14118983\"><span class=\"h2\">Exogenous factors that may affect HIV RNA levels</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Viral RNA levels can transiently rise during acute illness [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/25\" class=\"abstract_t\">25</a>], an outbreak of herpes simplex infection [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/26\" class=\"abstract_t\">26</a>], or vaccination against a variety of pathogens including influenza, pneumococcus, and tetanus [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/27,28\" class=\"abstract_t\">27,28</a>]. The increases may be quite dramatic, 1 log<sub>10</sub> (tenfold) or greater; however, values usually return to baseline within one month. Thus, plasma HIV-1 RNA levels should not be measured within one month of any of these events.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Relationship of HIV-1 RNA to CD4 cell count</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CD4 cell counts are correlated with viral RNA measurements, although the association is weak. In general, the higher the CD4 cell count, the lower the viral RNA. However, for any given CD4 cell count, there may be a 3 log<sub>10</sub> (1000-fold) range in viral RNA measurements [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/1,24\" class=\"abstract_t\">1,24</a>]. As an example, patients with a CD4 count of 200 <span class=\"nowrap\">cells/microL</span> may have HIV-1 RNA levels ranging from 1000 to 100,000 <span class=\"nowrap\">copies/mL</span>.</p><p>As a result, viral RNA measurements should <strong>not</strong> replace CD4 cell counts in the management of HIV-1-infected patients; rather, the two parameters should be used in parallel. CD4 cell counts are useful in determining when to initiate prophylactic therapy for opportunistic infections. (See <a href=\"topic.htm?path=techniques-and-interpretation-of-measurement-of-the-cd4-cell-count-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=overview-of-prevention-of-opportunistic-infections-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Overview of prevention of opportunistic infections in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">HIV-1 subtypes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV-1 is a genetically diverse virus that has been classified into three groups based upon significant differences in the sequence of the gag and envelope genes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Group M refers to the major group</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Group O refers to the outliers or outgroup</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Group N refers to non-M, non-O</p><p/><p>Group M is further divided into nine subtypes, referred to as subtypes A through D, F through H, J, K. The geographic distribution of the subtypes varies. The most common subtype in North America and Europe is subtype B; in the United States, strains other than subtype B are rare [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/29\" class=\"abstract_t\">29</a>], although there are reports of increasing genetic diversity of HIV-1 within the United States [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/30,31\" class=\"abstract_t\">30,31</a>]. Other subtypes, in particular A, C, D, and E, are commonly found in Africa and Asia [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/29\" class=\"abstract_t\">29</a>]. A more detailed discussion on the epidemiology of HIV is found elsewhere. (See <a href=\"topic.htm?path=global-epidemiology-of-hiv-infection\" class=\"medical medical_review\">&quot;Global epidemiology of HIV infection&quot;</a>.) </p><p>Most commercial assays were initially developed and evaluated for samples containing subtype B. The real-time HIV-1 RNA assays accurately quantify a wide range of HIV-1 subtypes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The COBAS <span class=\"nowrap\">AmpliPrep/COBAS</span> TaqMan version 2 HIV-1 test accurately quantifies all group M subtypes, group O, and many recombinants</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The RealTime HIV-1 test accurately quantifies all group M subtypes, group N, group O, and recombinants [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/32,33\" class=\"abstract_t\">32,33</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Aptima HIV-1 test accurately quantifies group M, N, and O, and many recombinants</p><p/><p>One study that compared various commercial assays with a second generation long terminal repeat-based PCR test demonstrated a high degree of correlation using samples that were genomically and geographically diverse [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/34\" class=\"abstract_t\">34</a>]. Any degree of discrepancy that was noted between assays was not associated with a specific subtype, but rather with the degree of genomic diversity within the subtype. A study evaluating the Aptima HIV-1 test using well characterized subtype samples demonstrated very good agreement in viral load values; 95 and 87 percent of the Aptima results where within 0.5 log10 of the COBAS TaqMan and RealTime results, respectively [<a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/35\" class=\"abstract_t\">35</a>]. </p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">AVAILABILITY AND COST OF VIRAL LOAD TESTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV-1 RNA measurements are widely available in clinical microbiology and reference laboratories. The cost of the assay varies from $80 to $240 per test. Cost should not be the only factor in determining where to have the testing performed; viral load assays are complex and should be performed by experienced laboratories. There are a variety of proficiency tests available to assist in assessing the performance of laboratories.</p><p class=\"headingAnchor\" id=\"H1585641043\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-hiv-screening-and-diagnostic-testing\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: HIV screening and diagnostic testing&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-hiv-treatment-in-nonpregnant-adults-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: HIV treatment in nonpregnant adults and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14118823\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Human immunodeficiency virus type 1 (HIV-1) RNA quantification (eg, viral load testing) is routinely used in the management of persons infected with HIV-1. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some studies have shown HIV-1 RNA levels to be a predictor of the time to progression to AIDS and death, independent of CD4 cell counts. Viral load measurements are also useful in determining the response to antiretroviral therapy. (See <a href=\"#H14118660\" class=\"local\">'The use of HIV viral load measurements'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are three real-time polymerase chain reaction tests that are widely used for viral load testing. For routine clinical use, viral load measurements are performed on plasma specimens. (See <a href=\"#H628267773\" class=\"local\">'Available tests'</a> above and <a href=\"#H3\" class=\"local\">'Specimen collection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some clinical laboratories test cerebral spinal fluid (CSF) specimens; however, this requires a separate validation process as HIV-1 RNA tests are not FDA approved for use on CSF. (See <a href=\"#H628267773\" class=\"local\">'Available tests'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients who are not taking antiretroviral therapy, there are small fluctuations of viral load that may be seen which are clinically insignificant. Changes in HIV-1 RNA levels must exceed at least 0.5 log<sub>10</sub> (or a threefold change in magnitude) to represent biologically relevant changes in viral replication. (See <a href=\"#H8\" class=\"local\">'Clinically significant changes in viral load'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Viral RNA levels can transiently rise during acute illness, an outbreak of herpes simplex infection, or after immunization. Thus, plasma HIV-1 RNA levels should not be measured within one month of any of these events. (See <a href=\"#H8\" class=\"local\">'Clinically significant changes in viral load'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CD4 cell counts are correlated with viral RNA measurements, although the association is weak. In general, the higher the CD4 cell count, the lower the viral RNA level. (See <a href=\"#H9\" class=\"local\">'Relationship of HIV-1 RNA to CD4 cell count'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/1\" class=\"nounderline abstract_t\">Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/2\" class=\"nounderline abstract_t\">O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996; 276:105.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/3\" class=\"nounderline abstract_t\">O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996; 334:426.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/4\" class=\"nounderline abstract_t\">Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996; 335:1091.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/5\" class=\"nounderline abstract_t\">Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997; 336:1337.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/6\" class=\"nounderline abstract_t\">Mellors JW, Mu&ntilde;oz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946.</a></li><li class=\"breakAll\">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on April 08, 2015).</li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/8\" class=\"nounderline abstract_t\">Schumacher W, Frick E, Kauselmann M, et al. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007; 38:304.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/9\" class=\"nounderline abstract_t\">Karasi JC, Dziezuk F, Quennery L, et al. High correlation between the Roche COBAS&reg; AmpliPrep/COBAS&reg; TaqMan&reg; HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes. J Clin Virol 2011; 52:181.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/10\" class=\"nounderline abstract_t\">Hopkins M, Hau S, Tiernan C, et al. Comparative performance of the new Aptima HIV-1 Quant Dx assay with three commercial PCR-based HIV-1 RNA quantitation assays. J Clin Virol 2015; 69:56.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/11\" class=\"nounderline abstract_t\">Sam SS, Kurpewski JR, Cu-Uvin S, Caliendo AM. Evaluation of Performance Characteristics of the Aptima HIV-1 Quant Dx Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 in Plasma and Cervicovaginal Lavage Samples. J Clin Microbiol 2016; 54:1036.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/12\" class=\"nounderline abstract_t\">Sch&oslash;nning K, Johansen K, Landt B, et al. Comparison of the Hologic Aptima HIV-1 Quant Dx Assay to the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Test v2.0 for the quantification of HIV-1 RNA in plasma samples. J Clin Virol 2017; 92:14.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/13\" class=\"nounderline abstract_t\">Swenson LC, Cobb B, Geretti AM, et al. Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol 2014; 52:517.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/14\" class=\"nounderline abstract_t\">Jain V, Liegler T, Kabami J, et al. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis 2013; 56:598.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/15\" class=\"nounderline abstract_t\">Dickover RE, Herman SA, Saddiq K, et al. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. J Clin Microbiol 1998; 36:1070.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/16\" class=\"nounderline abstract_t\">Holodniy M, Mole L, Yen-Lieberman B, et al. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J Clin Microbiol 1995; 33:1562.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/17\" class=\"nounderline abstract_t\">Holodniy M, Rainen L, Herman S, Yen-Lieberman B. Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. J Clin Microbiol 2000; 38:323.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/18\" class=\"nounderline abstract_t\">Garc&iacute;a-Bujalance S, Ladr&oacute;n de Guevara C, Gonz&aacute;lez-Garc&iacute;a J, et al. Elevation of viral load by PCR and use of plasma preparation tubes for quantification of human immunodeficiency virus type 1. J Microbiol Methods 2007; 69:384.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/19\" class=\"nounderline abstract_t\">Griffith BP, Mayo DR. Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in Plasma Preparation Tubes (PPT). J Clin Virol 2006; 35:197.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/20\" class=\"nounderline abstract_t\">Cao Y, Ho DD, Todd J, et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses 1995; 11:353.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/21\" class=\"nounderline abstract_t\">Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994; 170:553.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/22\" class=\"nounderline abstract_t\">Holodniy M, Mole L, Winters M, Merigan TC. Diurnal and short-term stability of HIV virus load as measured by gene amplification. J Acquir Immune Defic Syndr 1994; 7:363.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/23\" class=\"nounderline abstract_t\">Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996; 2:625.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/24\" class=\"nounderline abstract_t\">Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/25\" class=\"nounderline abstract_t\">Donovan RM, Bush CE, Markowitz NP, et al. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 1996; 174:401.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/26\" class=\"nounderline abstract_t\">Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176:766.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/27\" class=\"nounderline abstract_t\">O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995; 86:1082.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/28\" class=\"nounderline abstract_t\">Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995; 182:1727.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/29\" class=\"nounderline abstract_t\">Hu DJ, Dondero TJ, Rayfield MA, et al. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA 1996; 275:210.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/30\" class=\"nounderline abstract_t\">Cartwright CP. The changing epidemiology of HIV/AIDS at a Minnesota hospital: impact of demographic change and viral diversity. J Med Virol 2006; 78 Suppl 1:S19.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/31\" class=\"nounderline abstract_t\">Lin HH, Gaschen BK, Collie M, et al. Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J Acquir Immune Defic Syndr 2006; 41:399.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/32\" class=\"nounderline abstract_t\">Gueudin M, Plantier JC, Lem&eacute;e V, et al. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 2007; 44:500.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/33\" class=\"nounderline abstract_t\">Swanson P, Huang S, Abravaya K, et al. Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods 2007; 141:49.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/34\" class=\"nounderline abstract_t\">Rouet F, Chaix ML, Nerrienet E, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007; 45:380.</a></li><li><a href=\"https://www.uptodate.com/contents/techniques-and-interpretation-of-hiv-1-rna-quantitation/abstract/35\" class=\"nounderline abstract_t\">Manak MM, Hack HR, Nair SV, et al. Evaluation of Hologic Aptima HIV-1 Quant Dx Assay on the Panther System on HIV Subtypes. J Clin Microbiol 2016; 54:2575.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3743 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14118823\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H14118660\" id=\"outline-link-H14118660\">THE USE OF HIV VIRAL LOAD MEASUREMENTS</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">LABORATORY METHODS FOR QUANTITATION OF HIV-1 RNA</a><ul><li><a href=\"#H628267773\" id=\"outline-link-H628267773\">Available tests</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Specimen collection</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Quantification and linear range</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">INTERPRETATION</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Clinically significant changes in viral load</a></li><li><a href=\"#H14118983\" id=\"outline-link-H14118983\">Exogenous factors that may affect HIV RNA levels</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Relationship of HIV-1 RNA to CD4 cell count</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">HIV-1 subtypes</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">AVAILABILITY AND COST OF VIRAL LOAD TESTS</a></li><li><a href=\"#H1585641043\" id=\"outline-link-H1585641043\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H14118823\" id=\"outline-link-H14118823\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-and-early-hiv-infection-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Acute and early HIV infection: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=blood-donor-screening-laboratory-testing\" class=\"medical medical_review\">Blood donor screening: Laboratory testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hiv-2-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of HIV-2 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-testing-for-hiv-infection-in-infants-and-children-younger-than-18-months\" class=\"medical medical_review\">Diagnostic testing for HIV infection in infants and children younger than 18 months</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=factors-affecting-hiv-progression\" class=\"medical medical_review\">Factors affecting HIV progression</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=global-epidemiology-of-hiv-infection\" class=\"medical medical_review\">Global epidemiology of HIV infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hiv-associated-neurocognitive-disorders-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-prevention-of-opportunistic-infections-in-hiv-infected-patients\" class=\"medical medical_review\">Overview of prevention of opportunistic infections in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=patient-monitoring-during-hiv-antiretroviral-therapy\" class=\"medical medical_review\">Patient monitoring during HIV antiretroviral therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=screening-and-diagnostic-testing-for-hiv-infection\" class=\"medical medical_review\">Screening and diagnostic testing for HIV infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hiv-screening-and-diagnostic-testing\" class=\"medical medical_society_guidelines\">Society guideline links: HIV screening and diagnostic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hiv-treatment-in-nonpregnant-adults-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: HIV treatment in nonpregnant adults and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=techniques-and-interpretation-of-measurement-of-the-cd4-cell-count-in-hiv-infected-patients\" class=\"medical medical_review\">Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients</a></li></ul></div></div>","javascript":null}